This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on ISI (721)  • Contact me when this article is cited  Related Content  • Related letter  • Related article  • Similar articles in JAMA

Updated Recommendations of the International AIDS Society–USA Panel

Charles C. J. Carpenter, MD; David A. Cooper, MD, DSc; Margaret A. Fischl, MD; Jose M. Gatell, MD, PhD; Brian G. Gazzard, MA, MD; Scott M. Hammer, MD; Martin S. Hirsch, MD; Donna M. Jacobsen, BS; David A. Katzenstein, MD; Julio S. G. Montaner, MD; Douglas D. Richman, MD; Michael S. Saag, MD; Mauro Schechter, MD, PhD; Robert T. Schooley, MD; Melanie A. Thompson, MD; Stefano Vella, MD; Patrick G. Yeni, MD; Paul A. Volberding, MD

JAMA. 2000;283:381-390.

Objective  To update recommendations for antiretroviral therapy for adult human immunodeficiency virus type 1 (HIV-1) infection, based on new information and drugs that are available.

Participants  A 17-member international physician panel with antiretroviral research and HIV patient care experience initially convened by the International AIDS Society–USA in December 1995.

Evidence  Available clinical and basic science data including phase 3 controlled trials; data on clinical, virologic, and immunologic end points; research conference reports; HIV pathogenesis data; and panel expert opinion. Recommendations were limited to therapies available (US Food and Drug Administration approved) in 1999.

Consensus Process  The panel assesses new research reports and interim results and regularly meets to consider how the new data affect therapy recommendations. Recommendations are updated via full-panel consensus. Guidelines are presented as recommendations if the supporting evidence warrants routine use in the particular situation and as considerations if data are preliminary or incomplete but suggestive.

Conclusions  The availability of new antiretroviral drugs has expanded treatment choices. The importance of adherence, emerging long-term complications of therapy, recognition and management of antiretroviral failure, and new monitoring tools are addressed. Optimal care requires individualized management and ongoing attention to relevant scientific and clinical information in the field.

Author Affiliations: Brown University School of Medicine, Providence, RI (Dr Carpenter); University of New South Wales, Sydney, Australia (Dr Cooper); University of Miami School of Medicine, Miami, Fla (Dr Fischl); University of Barcelona, Barcelona, Spain (Dr Gatell); Chelsea and Westminster Hospital, London, England (Dr Gazzard); Columbia University College of Physicians and Surgeons, New York, NY (Dr Hammer); Harvard Medical School, Boston, Mass (Dr Hirsch); The International AIDS Society–USA, San Francisco, Calif (Ms Jacobsen); Stanford University Medical Center, Stanford, Calif (Dr Katzenstein); St Paul's Hospital, Vancouver, British Columbia (Dr Montaner); University of California, San Diego, and San Diego Veterans Affairs Medical Center (Dr Richman); University of Alabama at Birmingham (Dr Saag); Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil (Dr Schechter); University of Colorado School of Medicine, Denver (Dr Schooley); AIDS Research Consortium of Atlanta, Atlanta, Ga (Dr Thompson); Istituto Superiore di Sanità, Rome, Italy (Dr Vella); Hôpital Bichat-Claude Bernard, X. Bichat Medical School, Paris, France (Dr Yeni); and University of California, San Francisco (Dr Volberding).

RELATED LETTER

Effect of Ritonavir on Saquinavir Metabolism
Neil Buss and Charles C. J. Carpenter
JAMA. 2000;283(22):2936-2937.
EXTRACT | FULL TEXT  

RELATED ARTICLE

January 19, 2000
JAMA. 2000;283(3):411-412.
EXTRACT | FULL TEXT  

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Cost-Effectiveness of HIV Screening in Patients Older than 55 Years of Age
Sanders et al.
ANN INTERN MED 2008;148:889-903.
ABSTRACT | FULL TEXT  

The Cost-Effectiveness of Counseling Strategies to Improve Adherence to Highly Active Antiretroviral Therapy among Men Who Have Sex with Men
Zaric et al.
Med Decis Making 2008;28:359-376.
ABSTRACT  

Pharmacoepidemiological approach to the predisposing factors for highly active antiretroviral therapy failure in an HIV-positive cohort from Cordoba City (Argentina) 1995-2005
Soria et al.
Int J STD AIDS 2008;19:335-338.
ABSTRACT | FULL TEXT  

Highly Active Antiretroviral Therapy Use and HIV Transmission Risk Behaviors Among Individuals Who Are HIV Infected and Were Recently Released From Jail
Clements-Nolle et al.
Am. J. Public Health 2008;98:661-666.
ABSTRACT | FULL TEXT  

Immunological Responses and Long-Term Treatment Interruption after Human Immunodeficiency Virus Type 1 (HIV-1) Lipopeptide Immunization of HIV-1-Infected Patients: the LIPTHERA Study
Pialoux et al.
CVI 2008;15:562-568.
ABSTRACT | FULL TEXT  

Transcription Factor FOXO3a Mediates Apoptosis in HIV-1-Infected Macrophages
Cui et al.
J. Immunol. 2008;180:898-906.
ABSTRACT | FULL TEXT  

Comparative Evaluation of the Inhibitory Activities of a Series of Pyrimidinedione Congeners That Inhibit Human Immunodeficiency Virus Types 1 and 2
Buckheit et al.
Antimicrob. Agents Chemother. 2008;52:225-236.
ABSTRACT | FULL TEXT  

Correlations among measures of quality in HIV care in the United States: cross sectional study
Wilson et al.
BMJ 2007;335:1085-1085.
ABSTRACT | FULL TEXT  

Patient-related Factors Predicting HIV Medication Adherence among Men and Women with Alcohol Problems
Parsons et al.
J Health Psychol 2007;12:357-370.
ABSTRACT  

The Impact of Managed Care on Access to Highly Active Antiretroviral Therapy and on Outcomes among Medicaid Beneficiaries with AIDS
Zingmond et al.
Med Care Res Rev 2007;64:66-82.
ABSTRACT  

Life expectancy of patients with newly-diagnosed HIV infection in the era of highly active antiretroviral therapy
Fang et al.
QJM 2007;100:97-105.
ABSTRACT | FULL TEXT  

TRAIL-Mediated Apoptosis in HIV-1-Infected Macrophages Is Dependent on the Inhibition of Akt-1 Phosphorylation
Huang et al.
J. Immunol. 2006;177:2304-2313.
ABSTRACT | FULL TEXT  

A single centre cohort experience with a new once daily antiretroviral drug.
Stebbing et al.
Postgrad. Med. J. 2006;82:343-346.
ABSTRACT | FULL TEXT  

Evaluation of Antitumoral Properties of the Protease Inhibitor Indinavir in a Murine Model of Hepatocarcinoma
Esposito et al.
Clin. Cancer Res. 2006;12:2634-2639.
ABSTRACT | FULL TEXT  

DEPENDENCE OF NELFINAVIR BRAIN UPTAKE ON DOSE AND TISSUE CONCENTRATIONS OF THE SELECTIVE P-GLYCOPROTEIN INHIBITOR ZOSUQUIDAR IN RATS
Anderson et al.
Drug Metab. Dispos. 2006;34:653-659.
ABSTRACT | FULL TEXT  

Accurate prediction of HIV-1 drug response from the reverse transcriptase and protease amino acid sequences using sparse models created by convex optimization
Rabinowitz et al.
Bioinformatics 2006;22:541-549.
ABSTRACT | FULL TEXT  

Neutropenia in Human Immunodeficiency Virus Infection: Data From the Women's Interagency HIV Study.
Levine et al.
Arch Intern Med 2006;166:405-410.
ABSTRACT | FULL TEXT  

Quality of HIV Care Provided by Nurse Practitioners, Physician Assistants, and Physicians
Wilson et al.
ANN INTERN MED 2005;143:729-736.
ABSTRACT | FULL TEXT  

Psychosocial Factors Predict CD4 and Viral Load Change in Men and Women With Human Immunodeficiency Virus in the Era of Highly Active Antiretroviral Treatment
Ironson et al.
Psychosom. Med. 2005;67:1013-1021.
ABSTRACT | FULL TEXT  

Use of a Combined Ex Vivo/In Vivo Population Approach for Screening of Human Genes Involved in the Human Immunodeficiency Virus Type 1 Life Cycle for Variants Influencing Disease Progression
Bleiber et al.
J. Virol. 2005;79:12674-12680.
ABSTRACT | FULL TEXT  

Eosinophilic Folliculitis: Before and After the Introduction of Antiretroviral Therapy
Rajendran et al.
Arch Dermatol 2005;141:1227-1231.
ABSTRACT | FULL TEXT  

Physician Specialization and the Quality of Care for Human Immunodeficiency Virus Infection
Landon et al.
Arch Intern Med 2005;165:1133-1139.
ABSTRACT | FULL TEXT  

Cost-Effectiveness of Screening for HIV in the Era of Highly Active Antiretroviral Therapy
Sanders et al.
NEJM 2005;352:570-585.
ABSTRACT | FULL TEXT  

A randomized study comparing a three- and four-drug HAART regimen in first-line therapy (QUAD study)
Orkin et al.
J Antimicrob Chemother 2005;55:246-251.
ABSTRACT | FULL TEXT  

Resistance to enfuvirtide, the first HIV fusion inhibitor
Greenberg and Cammack
J Antimicrob Chemother 2004;54:333-340.
ABSTRACT | FULL TEXT  

Highly Active Antiretroviral Therapy and Cervical Squamous Intraepithelial Lesions in Human Immunodeficiency Virus-Positive Women
Ahdieh-Grant et al.
JNCI J Natl Cancer Inst 2004;96:1070-1076.
ABSTRACT | FULL TEXT  

Depressive Symptoms and AIDS-Related Mortality Among a Multisite Cohort of HIV-Positive Women
Cook et al.
Am. J. Public Health 2004;94:1133-1140.
ABSTRACT | FULL TEXT  

Medically Eligible Women Who Do Not Use HAART: The Importance of Abuse, Drug Use, and Race
Cohen et al.
Am. J. Public Health 2004;94:1147-1151.
ABSTRACT | FULL TEXT  

Effects of a Quality Improvement Collaborative on the Outcome of Care of Patients with HIV Infection: The EQHIV Study
Landon et al.
ANN INTERN MED 2004;140:887-896.
ABSTRACT | FULL TEXT  

Crystal Structures of a Multidrug-Resistant Human Immunodeficiency Virus Type 1 Protease Reveal an Expanded Active-Site Cavity
Logsdon et al.
J. Virol. 2004;78:3123-3132.
ABSTRACT | FULL TEXT  

Instrumental variables and inverse probability weighting for causal inference from longitudinal observational studies
Hogan and Lancaster
Stat Methods Med Res 2004;13:17-48.
ABSTRACT  

Incidence of Oral Lesions in HIV-1-infected Women: Reduction with HAART
Greenspan et al.
J. Dent. Res. 2004;83:145-150.
ABSTRACT | FULL TEXT  

Mitochondrial and Metabolic Effects of Nucleoside Reverse Transcriptase Inhibitors (NRTIs) in Mice Receiving One of Five Single- and Three Dual-NRTI Treatments
Note et al.
Antimicrob. Agents Chemother. 2003;47:3384-3392.
ABSTRACT | FULL TEXT  

Visceral adiposity, C-peptide levels, and low lipase activities predict HIV-dyslipidemia
Yarasheski et al.
Am. J. Physiol. Endocrinol. Metab. 2003;285:E899-E905.
ABSTRACT | FULL TEXT  

Adherence and plasma HIV RNA responses to highly active antiretroviral therapy among HIV-1 infected injection drug users
Wood et al.
CMAJ 2003;169:656-661.
ABSTRACT | FULL TEXT  

Shikonin, a Component of Chinese Herbal Medicine, Inhibits Chemokine Receptor Function and Suppresses Human Immunodeficiency Virus Type 1
Chen et al.
Antimicrob. Agents Chemother. 2003;47:2810-2816.
ABSTRACT | FULL TEXT  

Structure-based phenotyping predicts HIV-1 protease inhibitor resistance
Shenderovich et al.
Protein Sci. 2003;12:1706-1718.
ABSTRACT | FULL TEXT  

Alternation of Antiretroviral Drug Regimens for HIV Infection: A Randomized, Controlled Trial
Martinez-Picado et al.
ANN INTERN MED 2003;139:81-89.
ABSTRACT | FULL TEXT  

High Prevalence of M184 Mutation among Patients with Viroimmunologic Discordant Responses to Highly Active Antiretroviral Therapy and Outcomes after Change of Therapy Guided by Genotypic Analysis
Nicastri et al.
J. Clin. Microbiol. 2003;41:3007-3012.
ABSTRACT | FULL TEXT  

The Reliability of Reports of Medical Adherence From Children With HIV and Their Adult Caregivers
Dolezal et al.
J Pediatr Psychol 2003;28:355-361.
ABSTRACT | FULL TEXT  

Canadian consensus guidelines for the care of HIV-positive pregnant women: putting recommendations into practice
Burdge et al.
CMAJ 2003;168:1683-1688.
FULL TEXT  

Factors Affecting Patient Adherence to Highly Active Antiretroviral Therapy
Escobar et al.
The Annals of Pharmacotherapy 2003;37:775-781.
ABSTRACT | FULL TEXT  

Genetic Screen for Monitoring Hepatitis C Virus NS3 Serine Protease Activity
Martinez and Clotet
Antimicrob. Agents Chemother. 2003;47:1760-1765.
ABSTRACT | FULL TEXT  

Changes in CSF and plasma HIV-1 RNA and cognition after starting potent antiretroviral therapy
Marra et al.
Neurology 2003;60:1388-1390.
ABSTRACT | FULL TEXT  

When to Initiate Highly Active Antiretroviral Therapy: A Cohort Approach
Ahdieh-Grant et al.
Am J Epidemiol 2003;157:738-746.
ABSTRACT | FULL TEXT  

What's new for injection drug users with HIV infection?
Clarke and Mulcahy
Sex. Transm. Infect. 2003;79:80-83.
FULL TEXT  

Changes in the Human Immunodeficiency Virus p7-p1-p6 gag Gene in Drug-Naive and Pretreated Patients
Gallego et al.
J. Clin. Microbiol. 2003;41:1245-1247.
ABSTRACT | FULL TEXT  

Barriers to HAART Adherence Among Human Immunodeficiency Virus-Infected Adolescents
Murphy et al.
Arch Pediatr Adolesc Med 2003;157:249-255.
ABSTRACT | FULL TEXT  

Multicenter Evaluation of the Performance Characteristics of the NucliSens HIV-1 QT Assay Used for Quantitation of Human Immunodeficiency Virus Type 1 RNA
Ginocchio et al.
J. Clin. Microbiol. 2003;41:164-173.
ABSTRACT | FULL TEXT  

Early Factors in Successful Anti-HIV Treatment
Piliero
J Int Assoc Physicians AIDS Care (Chic Ill) 2003;2:10-20.
ABSTRACT  

Predictors of Psychological Well-Being in a Diverse Sample of HIV-Positive Patients Receiving Highly Active Antiretroviral Therapy
Safren et al.
Psychosomatics 2002;43:478-485.
ABSTRACT | FULL TEXT  

Improvement of Oral Drug Treatment by Temporary Inhibition of Drug Transporters and/or Cytochrome P450 in the Gastrointestinal Tract and Liver: An Overview
Kruijtzer et al.
The Oncologist 2002;7:516-530.
ABSTRACT | FULL TEXT  

Rate of Virological Treatment Failure and Frequencies of Drug Resistance Genotypes among Human Immunodeficiency Virus-Positive Subjects on Antiretroviral Therapy in Spain
Gallego et al.
J. Clin. Microbiol. 2002;40:3865-3866.
ABSTRACT | FULL TEXT  

Risk of Progression to AIDS and Death in Women Infected With HIV-1 Initiating Highly Active Antiretroviral Treatment at Different Stages of Disease
Anastos et al.
Arch Intern Med 2002;162:1973-1980.
ABSTRACT | FULL TEXT  

High Levels of Viral Replication Contrast with Only Transient Changes in CD4+ and CD8+ Cell Numbers during the Early Phase of Experimental Infection with Simian Immunodeficiency Virus SIVmnd-1 in Mandrillus sphinx
Onanga et al.
J. Virol. 2002;76:10256-10263.
ABSTRACT | FULL TEXT  

Human Immunodeficiency Virus Type 1 Genotypic and Pharmacokinetic Determinants of the Virological Response to Lopinavir-Ritonavir-Containing Therapy in Protease Inhibitor-Experienced Patients
Masquelier et al.
Antimicrob. Agents Chemother. 2002;46:2926-2932.
ABSTRACT | FULL TEXT  

Modulation of Human Immunodeficiency Virus (HIV)-Specific Immune Response by Using Efavirenz, Nelfinavir, and Stavudine in a Rescue Therapy Regimen for HIV-Infected, Drug-Experienced Patients
Trabattoni et al.
CVI 2002;9:1114-1118.
ABSTRACT | FULL TEXT  

Antiretroviral-Drug Resistance among Patients Recently Infected with HIV
Little et al.
NEJM 2002;347:385-394.
ABSTRACT | FULL TEXT  

Dual vs Single Protease Inhibitor Therapy Following Antiretroviral Treatment Failure: A Randomized Trial
Hammer et al.
JAMA 2002;288:169-180.
ABSTRACT | FULL TEXT  

Antiretroviral Treatment for Adult HIV Infection in 2002: Updated Recommendations of the International AIDS Society-USA Panel
Yeni et al.
JAMA 2002;288:222-235.
ABSTRACT | FULL TEXT  

Efficacy and Toxicity of Antiretroviral Therapy Using 4 or More Agents: Application of a Strategy for Antiretroviral Management in Human Immunodeficiency Virus-Infected Children
Melvin et al.
Arch Pediatr Adolesc Med 2002;156:568-573.
ABSTRACT | FULL TEXT  

Primer Unblocking and Rescue of DNA Synthesis by Azidothymidine (AZT)-resistant HIV-1 Reverse Transcriptase. COMPARISON BETWEEN INITIATION AND ELONGATION OF REVERSE TRANSCRIPTION AND BETWEEN (-) AND (+) STRAND DNA SYNTHESIS
Rigourd et al.
J. Biol. Chem. 2002;277:18611-18618.
ABSTRACT | FULL TEXT  

Systemic non-Hodgkin lymphoma in HIV-infected patients in the era of highly active antiretroviral therapy
Vilchez et al.
Blood 2002;99:4250-4251.
FULL TEXT  

Relationship of CD8+ T cell noncytotoxic anti-HIV response to CD4+ T cell number in untreated asymptomatic HIV-infected individuals
Castelli et al.
Blood 2002;99:4225-4227.
ABSTRACT | FULL TEXT  

Effects of a P-Glycoprotein Inhibitor on Brain and Plasma Concentrations of Anti-Human Immunodeficiency Virus Drugs Administered in Combination in Rats
Savolainen et al.
Drug Metab. Dispos. 2002;30:479-482.
ABSTRACT | FULL TEXT  

A prospective comparison of the two main indications of efavirenz in 2001 highly active antiretroviral therapy (HAART) regimens: first-line versus salvage use
Manfredi et al.
J Antimicrob Chemother 2002;49:723-729.
ABSTRACT | FULL TEXT  

Anti-Human Immunodeficiency Virus Interactions of SCH-C (SCH 351125), a CCR5 Antagonist, with Other Antiretroviral Agents In Vitro
Tremblay et al.
Antimicrob. Agents Chemother. 2002;46:1336-1339.
ABSTRACT | FULL TEXT  

DPC 817: a Cytidine Nucleoside Analog with Activity against Zidovudine- and Lamivudine-Resistant Viral Variants
Schinazi et al.
Antimicrob. Agents Chemother. 2002;46:1394-1401.
ABSTRACT | FULL TEXT  

Identifying Undiagnosed Human Immunodeficiency Virus: The Yield of Routine, Voluntary Inpatient Testing
Walensky et al.
Arch Intern Med 2002;162:887-892.
ABSTRACT | FULL TEXT  

Prophylaxis for Human Immunodeficiency Virus-Related Pneumocystis carinii Pneumonia: Using Simulation Modeling to Inform Clinical Guidelines
Goldie et al.
Arch Intern Med 2002;162:921-928.
ABSTRACT | FULL TEXT  

Evaluation of the Effectiveness of Highly Active Antiretroviral Therapy in Persons with Human Immunodeficiency Virus using Biomarker-based Equivalence of Disease Progression
Jacobson et al.
Am J Epidemiol 2002;155:760-770.
ABSTRACT | FULL TEXT  

Initial antiretroviral regimens
Carpenter
BMJ 2002;324:747-748.
FULL TEXT  

Systematic review and meta-analysis of evidence for increasing numbers of drugs in antiretroviral combination therapy
Jordan et al.
BMJ 2002;324:757-757.
ABSTRACT | FULL TEXT  

Pharmacokinetic Modeling and Simulations of Interaction of Amprenavir and Ritonavir
Sale et al.
Antimicrob. Agents Chemother. 2002;46:746-754.
ABSTRACT | FULL TEXT  

Evaluation and Management of HIV-Infected Women
Levine
ANN INTERN MED 2002;136:228-242.
ABSTRACT | FULL TEXT  

Structured Treatment Interruptions for the Management of HIV Infection
Lori and Lisziewicz
JAMA 2001;286:2981-2987.
ABSTRACT | FULL TEXT  

Differential Effects of HIV-1 Protease Inhibitors on Dendritic Cell Immunophenotype and Function
Gruber et al.
J. Biol. Chem. 2001;276:47840-47843.
ABSTRACT | FULL TEXT  

Predictors of Virologic and Clinical Outcomes in HIV-1-Infected Patients Receiving Concurrent Treatment with Indinavir, Zidovudine, and Lamivudine: AIDS Clinical Trials Group Protocol 320
Demeter et al.
ANN INTERN MED 2001;135:954-964.
ABSTRACT | FULL TEXT  

Ritonavir-Saquinavir Dual Protease Inhibitor Compared to Ritonavir Alone in Human Immunodeficiency Virus-Infected Patients
Michelet et al.
Antimicrob. Agents Chemother. 2001;45:3393-3402.
ABSTRACT | FULL TEXT  

Inhibitory Effects of Small-Molecule CCR5 Antagonists on Human Immunodeficiency Virus Type 1 Envelope-Mediated Membrane Fusion and Viral Replication
Takashima et al.
Antimicrob. Agents Chemother. 2001;45:3538-3543.
ABSTRACT | FULL TEXT  

Pharmacokinetic Study of Human Immunodeficiency Virus Protease Inhibitors Used in Combination with Amprenavir
Sadler et al.
Antimicrob. Agents Chemother. 2001;45:3663-3668.
ABSTRACT | FULL TEXT  

HIV Viral Load Response to Antiretroviral Therapy According to the Baseline CD4 Cell Count and Viral Load
Phillips et al.
JAMA 2001;286:2560-2567.
ABSTRACT | FULL TEXT  

Rates of Disease Progression by Baseline CD4 Cell Count and Viral Load After Initiating Triple-Drug Therapy
Hogg et al.
JAMA 2001;286:2568-2577.
ABSTRACT | FULL TEXT  

Initiating Antiretroviral Therapy During HIV Infection: Confusion and Clarity
Pomerantz
JAMA 2001;286:2597-2599.
FULL TEXT  

Reduced blood CD123+ (lymphoid) and CD11c+ (myeloid) dendritic cell numbers in primary HIV-1 infection
Pacanowski et al.
Blood 2001;98:3016-3021.
ABSTRACT | FULL TEXT  

DPC 681 and DPC 684: Potent, Selective Inhibitors of Human Immunodeficiency Virus Protease Active against Clinically Relevant Mutant Variants
Kaltenbach et al.
Antimicrob. Agents Chemother. 2001;45:3021-3028.
ABSTRACT | FULL TEXT  

Drugs and Cardiotoxicity in HIV and AIDS
FANTONI et al.
Ann. N. Y. Acad. Sci. 2001;946:179-199.
ABSTRACT | FULL TEXT  

Role of Guidelines in Clinical Practice for the Management of HIV-Related Diseases
LAURIA et al.
Ann. N. Y. Acad. Sci. 2001;946:310-323.
ABSTRACT | FULL TEXT  

Cost-Effectiveness of Earlier Initiation of Antiretroviral Therapy for Uninsured HIV-Infected Adults
Schackman et al.
Am. J. Public Health 2001;91:1456-1463.
ABSTRACT | FULL TEXT  

Transport Characteristics of the Anti-human Immunodeficiency Virus Nucleoside Analog, Abacavir, into Brain and Cerebrospinal Fluid
Thomas et al.
J. Pharmacol. Exp. Ther. 2001;298:947-953.
ABSTRACT | FULL TEXT  

HIV care in non-industrialised countries
Gilks
Br Med Bull 2001;58:171-186.
ABSTRACT | FULL TEXT  

Antiretroviral Therapy for Previously Treated Patients
Montaner and Mellors
NEJM 2001;345:452-455.
FULL TEXT  

Dual nucleoside analogue treatment in the era of highly active antiretroviral therapy (HAART): a single-centre cross-sectional survey
Manfredi et al.
J Antimicrob Chemother 2001;48:299-302.
ABSTRACT | FULL TEXT  

Variants Other than Aspartic Acid at Codon 69 of the Human Immunodeficiency Virus Type 1 Reverse Transcriptase Gene Affect Susceptibility to Nucleoside Analogs
Winters and Merigan
Antimicrob. Agents Chemother. 2001;45:2276-2279.
ABSTRACT | FULL TEXT  

The Effects of Recombinant Human Growth Hormone on Body Composition and Glucose Metabolism in HIV-Infected Patients with Fat Accumulation
Lo et al.
J. Clin. Endocrinol. Metab. 2001;86:3480-3487.
ABSTRACT | FULL TEXT  

Successful Testing Protocols in Virology
Kelley and Caliendo
Clin. Chem. 2001;47:1559-1562.
ABSTRACT | FULL TEXT  

Is It Justifiable to Withhold Treatment for Hepatitis C from Illicit-Drug Users?
Edlin et al.
NEJM 2001;345:211-214.
FULL TEXT  

Prevalence and Predictive Value of Intermittent Viremia With Combination HIV Therapy
Havlir et al.
JAMA 2001;286:171-179.
ABSTRACT | FULL TEXT  

Durable HIV Treatment Benefit Despite Low-Level Viremia: Reassessing Definitions of Success or Failure
Deeks
JAMA 2001;286:224-226.
FULL TEXT